How payer-participating trials could help transform clinical research on FDA-approved drugs; Access to new tools to combat RSV in babies likely to prove challenging

Taking stock of the drug industry, from the lab to the medicine chest

October 6, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Opinion: How payer-participating trials could help transform clinical research on FDA-approved drugs This new approach could augment clinical evidence and enhance patient-centric care across various therapeutic areas, including in Alzheimer's. By Vijay Ramakrishnan Access to new tools to combat RSV in babies likely to prove challenging The effort to prevent viral infection in babies could be complicated as doctors, birthing hospitals, and others scurry to make arrangements. By Helen Branswell STAT+ | Judge dismisses Novo Nordisk lawsuit over compounded versions of Ozempic and Wegovy The drug maker accused several compounders of selling versions of its medicines that were never approved by the Food and Drug Administration. By Ed Silverman Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser